Biotech Stocks


Biotech Stocks

Biotechnology has been one of the fastest advancing industries in the past decade. With new medicine always being synthesized and new ways to fertilize crops, the sector is diverse and prosperous, especially as corporations look for new findings or better efficiency. Subsequently, the biotech stocks are booming and should continue to rise in the future.
Some of the best biotech stocks to buy in 2014 include Amgen (NYSE:AMGN) and Gilead Sciences (NYSE:GILD) although many smaller biotech corporations are on the rise and worth a consideration. Biotech stocks can cure your ailing portfolio and lead you down the road to recovery.

Biotechnology Sector Quote (CIX: MSECTOR5151)

Wall Street’s 5 Hottest Biotech Stocks Right Now

By Harriet Lefton, Writer, TipRanks
These five top biotech stocks have the seal of approval from the Street, with 'strong buy' analyst consensus ratings and big upside.

3 Cheap Biotech Stocks The Big Boys Are Buying (BLRX, OMED, FWP)

By
Biotechnology is among the most exciting and lucrative sectors for investors, and these 3 biotech stocks stand out...

Is Now the Time to Buy Into These 5 Biotech ETFs?

By
After a painful 2016, biotech stocks are recovering this year. What lies ahead? Let's look at 5 biotech ETFs to find out

Biogen Inc (BIIB) Stock Needs a Biotech Bounceback

By Chris Fraley, InvestorPlace Contributor
Biogen just beat fourth-quarter earnings. But BIIB stock won't really get going until the biotech sector as a whole does.

5 Top Biotech Stocks to Buy on Trump Victory

By
The case for buying biotech stocks has strengthened following the election of Donald Trump to the White House.

The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is at a Critical Level

By Serge Berger, InvestorPlace Contributor
The iShares Nasdaq Biotechnology ETF (IBB) has dwindled over the past few weeks. Now, it's on a hair-thin line of support that bulls and bears alike should watch.

Celgene Corporation (CELG) – Two Ways to Trade CELG Stock

By Serge Berger, InvestorPlace Contributor
CELG stock now sits at a critical technical juncture with two paths to take after Celgene experienced a wild ride in late July and August.

The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is on Breakout Watch!

By Serge Berger, InvestorPlace Contributor
The iShares Nasdaq Biotechnology ETF (IBB) has settled into a constructive-looking phase. The path of least resistance? North!

Amgen, Inc (AMGN) – Amgen Stock Is a Powerhouse

By Serge Berger, InvestorPlace Contributor
Biotechs such as Amgen stock have been riding high for more than a month. AMGN in particular looks promising for new money.

Novavax, Inc.: NVAX Stock Gets Gutted — Can It Still Double?

By John Kilhefner, Senior Managing Editor, Lango Franchise
Novavax, Inc. (NASDAQ:NVAX) is leading the biotech charge downward today on dismal earnings that left investors questioning the bull case.

The iShares Nasdaq Biotechnology Index (ETF) (IBB) — It’s Make-or-Break Time

By Serge Berger, InvestorPlace Contributor
While the intermediate-term trend remains intact for the IBB etf, earnings season for large biotech companies could be make-or-break.

The iShares Nasdaq Biotechnology Index (ETF) (IBB): Gravity Calls!

By Serge Berger, InvestorPlace Contributor
Active investors and traders should look to play the iShares Nasdaq Biotechnology Index (ETF) (IBB) to the short side until the picture changes.

ABBV Stock: Could AbbVie Inc’s Gamble on Stemcentrx Pay Off?

By Craig Adeyanju, InvestorPlace Contributor
Stemcentrx's acquisition does little to alleviate the risk of the potential decrease in sales once Humira loses patent protection.

iShares Nasdaq Biotechnology Index (ETF) (IBB): Nibble on the Long Side

By Serge Berger, InvestorPlace Contributor
Biotech stocks, after some prolonged weakness, are starting to show promising relative and absolute strength. That means opportunity in the IBB.

Trade of the Day: Nautilus, Inc. (NYSE:NLS)

By Jon Markman, Editor, Trader's Advantage and CounterPoint Options
Nautilus (NLS) shares fell 3.7% Monday on no news, offering traders a phenomenal entry point.

Opko Health Inc.: FDA Denial Won’t Kill OPK

By Craig Adeyanju, InvestorPlace Contributor
The approval delay of Rayaldee, Opko Health's new billion-dollar drug, won't hurt its market performance. OPK is a high-risk/high-reward stock.

Gilead Sciences, Inc.: GILD Could Squeeze the Bears From Here

By Serge Berger, InvestorPlace Contributor
Gilead Sciences enjoyed a rally Monday along with the rest of the biotech sector. This breakout could be followed up by a short squeeze in GILD stock.

3 Biotech Stocks That Are Ripe for a Fall

By Profit Scanner
Biotech stocks are looking particularly weak right now, and these three companies in specific still have more downside to explore.

The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is a Buy, But Not for Long

By Serge Berger, InvestorPlace Contributor
The iShares Nasdaq Biotechnology ETF (IBB) has yet to pull off something that other parts of the market have -- and that spells opportunity in IBB.
Load More